Table 1 Baseline characteristics and follow-up data of the two groups

Age (years)

55 ± 15

52 ± 13

59 ± 16

0.178

Sex (M/F)

25/7

13/4

12/3

0.261

Baseline

 Urinary protein (g/24 h)

8.5 ± 3.6

8.1 ± 3.4

8.9 ± 3.9

0.509

 Serum albumin (g/L)

24.8 ± 3.4

25.8 ± 2.9

23.6 ± 3.6

0.069

 eGFR (mL/min/1.73m²)

88 ± 25

91 ± 24

85 ± 27

0.491

 anti-PLA2R titer (RU/mL)

320 ± 511

62 ± 39

611 ± 637

0.005

 CD19 + B cell (/mm³)

226 ± 128

211 ± 117

237 ± 141

0.642

 Immunoglobulin G (g/L)

6.1 ± 2.5

5.4 ± 1.4

6.8 ± 3.1

0.109

6 months

 Urinary protein (g/24 h)

3.7 ± 3.0

3.4 ± 3.2

4.1 ± 2.9

0.530

 Serum albumin (g/L)

32.2 ± 5.2

33.5 ± 4.5

30.8 ± 5.7

0.172

 eGFR (mL/min/1.73m²)

85 ± 26

95 ± 25

74 ± 23

0.023

 anti-PLA2R titer (RU/mL)

69 ± 264

4 ± 6

135 ± 367

0.203

 CD19 + B cell (/mm³)

14 ± 30

21 ± 40

8 ± 15

0.294

 Immunoglobulin G (g/L)

7.7 ± 2.4

7.3 ± 2.1

8.0 ± 2.6

0.507

 rituximab cumulative dose (mg)

525 ± 139

476 ± 130

580 ± 108

0.021

12 months

 Urinary protein (g/24 h)

1.8 ± 2.1

1.0 ± 1.2

2.7 ± 2.5

0.028

 Serum albumin (g/L)

36.7 ± 6.2

39.6 ± 3.9

33.4 ± 6.8

0.007

 eGFR (mL/min/1.73m²)

82 ± 25

88 ± 24

74 ± 25

0.115

 anti-PLA2R titer (RU/ml)

8 ± 33

1 ± 2

17 ± 49

0.279

 CD19 + B cell (/mm³)

33 ± 70

48 ± 89

14 ± 22

0.246

 Immunoglobulin G (g/L)

9.9 ± 3.2

10.6 ± 3.3

9.1 ± 3.0

0.298

 rituximab cumulative dose (mg)

747 ± 253

659 ± 255

847 ± 217

0.033

 PR + CR, n (%)

25 (78)

16 (94)

9 (60)

0.020

 CR, n (%)

8 (25)

6 (35)

2 (6)

0.152

18 months

 Urinary protein (g/24 h)

1.8 ± 3.0

1.4 ± 3.7

2.2 ± 1.8

0.445

 Serum albumin (g/L)

39.3 ± 5.7

41.3 ± 5.4

37.0 ± 5.4

0.033

 eGFR (mL/min/1.73m²)

79 ± 21

84 ± 19

74 ± 22

0.274

 anti-PLA2R titer (RU/ml)

2 ± 3

1 ± 1

3 ± 4

0.092

 rituximab cumulative dose (mg)

819 ± 351

694 ± 270

960 ± 387

0.030

 PR + CR, n (%)

27 (84)

16 (94)

11 (73)

0.106

 CR, n (%)

11 (34)

9 (53)

2 (13)

0.000

B-cell depletion

 Time for B cell depletion (m)

1.1 ± 0.4

1.1 ± 0.4

1.1 ± 0.4

0.994

 rituximab dose for B cell depletion (mg)

113 ± 34

112 ± 33

107 ± 26

0.898

Time to anti-PLA2R titer decrease (m)

 ≥ 50%

1.4 ± 0.8

1.1 ± 0.5

1.7 ± 1.0

0.062

 ≥ 90%

4.1 ± 3.5

3.5 ± 3.4

4.8 ± 3.5

0.308

 < 2 (RU/mL)

7.0 ± 5.0

5.8 ± 5.1

8.8 ± 4.6

0.126

rituximab cumulative dose for anti-PLA2R titer decrease (mg)

 ≥ 50%

137 ± 55

124 ± 44

153 ± 64

0.142

 ≥ 90%

341 ± 251

253 ± 128

440 ± 318

0.033

 < 2 (RU/mL)

507 ± 362

335 ± 169

750 ± 427

0.007